Keymed Biosciences, Inc. (HK:2162) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Keymed Biosciences Inc. has reported promising long-term efficacy and safety results from a Phase III clinical trial of stapokibart injection for treating moderate-to-severe atopic dermatitis, with sustained benefits and no new safety issues over a 52-week period. The data, presented at the European Academy of Allergy and Clinical Immunology Congress 2024, shows significant improvement in symptoms and quality of life for patients. The company cautions that while results are encouraging, there is no guarantee of successful development or commercialization.
For further insights into HK:2162 stock, check out TipRanks’ Stock Analysis page.